Ernexa Therapeutics (ERNAW) Return on Invested Capital (2011 - 2026)

Ernexa Therapeutics has reported Return on Invested Capital for 16 years, with the latest figure at 0.03% in Q1 2026.

• For the quarter ending Q1 2026, Return on Invested Capital fell 9.0% year-over-year to 0.03%; the trailing twelve-month figure through Mar 2026 stood at 0.03% (down 9.0% YoY), and the FY2025 full-year result was 0.04%, up 2.0% from the prior year.
• Return on Invested Capital for Q1 2026 stood at 0.03%, up from 0.03% in the prior quarter.
• The five-year high for Return on Invested Capital was 0.37% in Q1 2024, with the low at 0.07% in Q4 2023.
• Historically, Return on Invested Capital has averaged 0.01% across 5 years, with a median of 0.03% in 2023.
• Annual changes were most pronounced in 2024 — Return on Invested Capital soared 39 bps — and 2025, when it sank 31 bps.
• Ernexa Therapeutics' Return on Invested Capital stood at 0.03% in 2022, then sank by 149 bps to 0.07% in 2023, then soared by 109 bps to 0.01% in 2024, then tumbled by 548 bps to 0.03% in 2025, then climbed by 16 bps to 0.03% in 2026.
• The last three Return on Invested Capital figures came in at 0.03% (Q1 2026), 0.03% (Q4 2025), and 0.02% (Q3 2025), per Business Quant data.